involving the developing central nervous system, endocrine system and skeletal system, can be avoided. Busulfan pharmacokinetics have been studied since We analyzed plasma pharmacokinetics of busulfan in 64 children and young adults (age 2.8-26; median 11
Several other studies reported the relationship between high phosphamide 120 or 200 mg/kg. Three sets of parameters were examined in this homogenous patient popubusulfan plasma levels and drug-related toxicities, namely hepatic veno-occlusive disease (VOD) and seizures. 3, 4 An lation: (1) factors that affect the plasma kinetics of busulfan, such as age and pre-transplant liver status inverse correlation was seen between steady-state busulfan plasma concentration and graft rejection in unrelated donor defined by liver function tests, ferritin levels and liver biopsy; (2) busulfan-related toxicity: occurrence of BMT in patients with multiple diagnosis. 5 However, all previous studies were conducted analyzing veno-occlusive disease, seizures and idiopathic interstitial pneumonitis; and (3) the relationship between heterogeneous patient populations. There has been no study in a large, uniform group of patients with a single disease, busulfan exposure and transplant outcome: engraftment delay or rejection, aplasia, occurrence of mixed without pre-transplant chemotherapy.
We analyzed plasma pharmacokinetics of busulfan in 64 chimeras and mortality. Kinetic analysis of first and 10th dose (using area under the curve (AUC), maximum children and young adults with homozygous ␤-thalassemia transplanted with histocompatable sibling bone marrow. A and minimum concentration) as comparable, showing no sign of accumulation or decline in busulfan plasma uniform conditioning regimen was employed, using busulfan 14 or 16 mg/kg and CY 120 or 200 mg/kg. Busulfan levels over time. Age and liver status did not influence busulfan metabolism. No relationship was found clearance in relation to age and pre-transplant liver status was assessed and the relationship of busulfan exposure to between busulfan exposure and toxicities or transplant outcome. We conclude that busulfan monitoring is not engraftment, graft rejection and toxicities was studied. predictive in children and young adults with homozygous ␤-thalassemia receiving busulfan and high-dose cyclophosphamide along with histocompatable sibling Materials and methods donor marrow. Keywords: bone marrow transplantation; busulfan;
Patient population pharmacokinetics; thalassemia From March 1990 to June 1991, 64 children and young adults with homozygous ␤-thalassemia underwent bone marrow transplantation from genotypically HLA-identical Busulfan is a fundamental part of myeloablative regimens sibling donors at the Center for Bone Marrow Transplanused for patients undergoing bone marrow transplantation tation of Muraglia, Pesaro, Italy. Patient ages ranged from for malignant and non-malignant conditions. High-dose 2.8 to 26 years (median 11 years). Eleven patients (17%) busulfan in combination with cyclophosphamide (CY) is were older than 18 years of age. Conditioning consisted of particularly attractive in children, as significant total body busulfan 14 mg/kg and CY 200 mg/kg (50 mg/kg/dose ϫ 4 irradiation-related mortality and morbidity, especially daily doses) with CsA alone as GVHD prophylaxis (regimen A) or busulfan 14 or 16 mg/kg, CY 120 mg/kg (60 mg/kg/dose ϫ 2 daily doses) with CsA, CY (7.5 mg/kg B). The conditioning regimen was selected based on the HPLC assay for busulfan patient's disease class. Degree of hepatomegaly (Ͼ2 cm A modification of the previously described HPLC assay for below the costal margin), presence of portal fibrosis and busulfan was used for specimen analysis. 9 Standard curves, quality of chelation during the years before transplant were run with each batch of patient samples analyzed, were used used to divide patients into three classes according to the to quantitate busulfan. Busulfan (kindly supplied by Burabsence of all risk factors (class 1), the presence of one or roughs-Welcome, Research Triangle Park, NC, USA) was two factors (class 2), or the presence of all three (class 3). dissolved in ethyl acetate at a concentration of 75 m. To Patients in class 1 and 2 were prepared for transplantation generate busulfan standard curves the stock solution was using regimen A, and patients in class 3 were given regifurther diluted in plasma to the following concentrations men B 6, 7 (Table 1) . Bone marrow infused on day 0 conprior to analysis: 0.5, 1.0, 2.5, 5.0, 10 m. teinized and the residue obtained with diethyl-dithioAnticonvulsant prophylaxis during busulfan adminiscarbamic acid trihydrate (DDTC; Aldrich Chemical Co, tration included clonazepam (56 patients), phenytoin (three Milwaukee, WI, USA) prior to HPLC analysis. The DDTC patients), phenytoin and clonazepam (four patients), clonasolution was made weekly by washing DDTC with 50 ml zepam and phenobarbital (one patient who was on phenoof ethyl acetate and adding 2.5 g to 50 ml of distilled water barbital for several years prior to the transplant).
(5%). The DDTC solution was demonstrated to be stable All patients underwent liver biopsy before transplanfor longer than 1 week. One milliliter of methanol was tation. Grading systems were established to record sideadded to 0.5 ml of plasma, vortexed briefly and incubated rosis, chronic active hepatitis, chronic persistent hepatitis, for 20 min at −20°C. Tubes were spun, 0.6 ml of the superand portal fibrosis as seen on liver biopsy. Three grades of natant was transferred to glass screw-top tubes and 0.6 ml severity (mild, moderate and severe) were identified for of 100 mm ammonium acetate buffer and 0.3 ml of 5% each diagnostic category.
8 Plasma ferritin level, SGOT and DDTC solution was added. After mixing, the residue was total bilirubin were also obtained pre-BMT.
allowed to stand at room temperature for 10 min. The busBusulfan was administered orally as a tablets over 4 days ulfan-DDTC derivative was then extracted by adding 1.5 every 8 h. In some instances the tablets were crushed and ml of ethyl acetate, vortexing and spun for 3 min (Sorval suspended in water at a concentration of 2 mg/ml. The GLC-2, 3000 r.p.m.). One milliliter of the top (ethyl actual individual dose for pharmacokinetic analysis ranged acetate) layer was transferred to glass tubes and dried at from 1.00 to 1.85 mg/kg (mean Ϯ s.d. = 1.2 Ϯ 0.12, median room temperature in nitrogen. The residue was resuspended 1.17). Over the course of therapy, individual doses were in 200 l of methanol and 100 l injected via an autoinjecadjusted to give a total dose of 14 or 16 mg/kg, and thus tor for analysis (Gilson model 231; Gilson Medical Elecwere not identical. Data from patients who vomited followtronics, Middleton, WI, USA). The mobile phase used was ing busulfan administration were not included in the 80% methanol/20% water by volume at a flow rate of 1.5 analysis.
ml/min. Absorbency at 251 nm was monitored with a UV detector (Gilson model 115) set at a sensitivity of 0.01 AUFS. The Busulfan-DDTC derivative was typically eluted at 14 min following injection. The slope of a composite Specimen collection and stability of all standard curves was used to calculate the busulfan concentration in the unknown patient specimens. Patient specimens were collected for analysis at the following times after the first and 10th dose: 0, 30, 60, 90, 120, 180, 360 min. The first dose pharmacokinetics were anaPharmacokinetic modeling lyzed for all patients. Specimens for analysis of the 10th dose were obtained from 47 patients. Specimens were colUsing a personal computer, pharmacokinetic parameters were estimated by an iterative program to fit a first-order lected in EDTA, spun, and the plasma removed and frozen for transport. Studies have shown busulfan is stable for over one-compartment model (MK Model; Biosoft, Milltown, NJ, USA). The following parameters were estimated from 3 months in frozen plasma. Busulfan pharmacokinetics studies were performed at the University of Minnesota, the raw data using the model: clearance (Cl, l/min/kg); volume of distribution (VD, l/kg); and absorption rate constant Minneapolis. from the fall-off data.
EL L 1.5 1.9 ± 1.6 0.4-9.1 AUC = area under curve normalized to a dose of 1 mg/kg (m*min).
Outcome parameters
To convert to an average steady-state concentration (ng gain and increase in bilirubin. 10 The diagnosis of idiopathic interstitial pneumonitis was made on a radiograph when an change in AUC, Cmax, Cmin following dose normalization infectious agent was not found.
to 1 mg/kg. Post-transplant engraftment was determined by an
Comparison of first and 10th dose kinetics revealed that increase in the granulocyte count (ANC Ͼ5 × 10 8 /l), cytothey are similar, being within 20% of each other the genetic analysis when the donor and recipient were of majority (90%) of the time. For AUC, Cmax, CL, VD there opposite sex and globin chain synthesis evaluation by colis a significant difference in the distribution between first umn chromatography. Graft rejection was defined as a loss and last dose, but the mean difference is small (Ͻ10%) of documented donor engraftment with return of autologous and therefore probably not of biological significance. The marrow. Occurrence of mixed chimerism was evaluated by differences between the first and 10th dose are of small DNA study at 60-120 days post-BMT. 11 magnitude (Ͻ20%) for the most part, suggesting that there Acute and chronic graft-versus-host disease was graded is no need to determine both. The data indicate no busulfan according to the Seattle criteria. 12 accumulation or decrease in exposure with subsequent doses due to changes in metabolism, as has been reported Statistical analysis with phenytoin. There is no significant association between pharmacokiThree sets of parameters were examined: factors that might netic parameters and age. The mean clearance of busulfan affect the pharmacokinetics of busulfan (eg age, pre-transin our study was approximately twice that reported in adults plant liver function tests, ferritin levels); possible drugand similar to values previously reported in young chilrelated toxicity (eg VOD, seizures, interstitial pneumonitis), dren. 2 Analysis comparing busulfan pharmacokinetics in and transplant outcome (eg aplasia, engraftment delay or children 5 years of age and younger (n = 7) with patients rejection, mixed chimerism, and mortality). t-test, ANOVA, older than 5 years (n = 57) showed no statistical difference. and multiple linear regression were employed in evaluating Patient pre-BMT clinical status was characterized by predictors of busulfan pharmacokinetics, and in assessing results of liver biopsy, SGOT, total bilirubin, ferritin and the association of busulfan pharmacokinetics with toxicity. assigned a disease class, summarized in Tables 3 and 4 
. Kaplan-Meier product limit method and Cox regression
There is a significant correlation between ferritin level and analysis were applied to evaluate the effect of busulfan pharmacokinetics on time to engraftment and survival, censoring patients at death for engraftment and last contact Table 3 Pre-transplant liver status -biopsy results for survival. Pharmacokinetic parameters normalized to a busulfan dose CAH = chronic active hepatitis; CPH = chronic persistent hepatitis.
of 1 mg/kg are summarized in Table 2 for the entire patient
Biopsies from two patients were not evaluable for hepatitis and biopsy from one patient was not evaluable for siderosis and fibrosis.
group. Due to the small dose range there was insignificant 
Busulfan concentration and toxicities
In our patient population the incidence of VOD was 4.5% disease class, degree of siderosis, degree of fibrosis and (three patients), interstitial pneumonitis 11% (seven SGOT (P = 0.0005, P = 0.0001, P = 0.0001, P = 0.0001, patients), early onset seizures 7% (five episodes before day respectively). However, there is no correlation between pre-+30 post-BMT). No seizures during administration of bustransplant liver status or the class and busulfan pharmacoulfan were documented. Busulfan plasma level was not kinetics.
associated with these events although only one patient had an AUC previously associated by Grochow with a higher Busulfan concentration and outcome risk of VOD. 3 Two patients diagnosed with VOD received CY doses of 200 mg/kg, and one received a CY dose of Marrow recovery (ANC Ͼ0.5 × 10 9 /l) occurred on days 120 mg/kg. VOD was significantly (P Ͻ 0.006) associated 13-37, with a medium of 18 days. Busulfan exposure, CY with ferritin ( Figure 1 ) levels as well as with degree of dose and type of GVHD prophylaxis did not affect time to siderosis on liver biopsy. Three of 20 patients with severe neutrophil recovery.
siderosis were diagnosed with VOD, in contrast to 0 of 43 The influence of busulfan on the incidence of graft rejecwith mild or moderate siderosis (P = 0.02). tion (five rejections were observed, a total of 7.5%) was
To eliminate the potential influence of different CY not evident. No difference in pharmacokinetic parameters doses and GVHD prophylaxis regimens on transplant outwas observed for patients who rejected their graft as comcome and toxicities, additional analyses were conducted on pared to those with sustained engraftment. However, only patients with class 1 and 2 disease. There was no significant six patients had average steady-state concentrations below relationship between busulfan exposure and transplant out-200 ng/ml, the range of increased rejection for HLA come in the 36 patients who received busulfan 14 mg/kg, matches reported by Slattery et al, 5 and none rejected. CY 200 mg/kg and CsA only as a GVHD prophylaxis. Rejection was associated with CY dose (5/27 rejected when treated with 120 mg/kg vs 0/30 with 200 mg/kg, P = 0.02) and GVHD prophylaxis (5/23 rejection noted with Discussion CsA/ALG/MTX vs 0/36 with CsA, P = 0.02). As the patients treated with CY 120 mg/kg also received Our study was conducted on a homogenous patient popuCsA/ALG/MTX it is impossible to identify the effect of lation transplanted with bone marrow from HLA-matched CY and GVHD prophylaxis on graft rejection. genotypically identical siblings. In this group there was no There was no significant relationship between busulfan association of busulfan pharmacokinetics with age or with exposure and late aplasia, which occurred in five patients (7.5%), or the incidence of mixed chimerism (27%, on an Analysis conducted in such a homogenous group of confirmed the increased occurrence of VOD with AUC Ͻ1500 m*min. They also noted a significant decrease in patients can ensure a more accurate assessment of regimenrelated toxicities because of the uniformity of the pre-transincidence of VOD in patients receiving reduced doses of busulfan from the 5th to the 16th doses as compared to plant treatment regimen and clinical status. Such an analysis allows us to correlate busulfan pharmacokinetics more patients without dose reduction. However, Schuler et al 21 were unable to correlate busulfan pharmacokinetics paradirectly with treatment outcome.
Initial evaluation of low-dose oral busulfan in adults (2, meters with the risk of VOD in adults with CML receiving HLA-identical BMT, a disease with decreased risk of VOD. 4 and 6 mg dose) by Ehrsson et al 13 was followed by studies of high-dose busulfan (1 mg/kg) conducted by the same Also, a single daily dose regimen (4 mg/kg/dose), which resulted in a four-fold higher Cmax and AUC values (dose group. Analysis of first and last dose pharmacokinetics showed no evidence of busulfan accumulation over time.
adjusted) was not associated with an increase in VOD incidence. 22 A trial conducted by Demirer et al 23 attempted to Subsequent studies had variable results with one being confirmatory 4 and others showing either increases or decreases decrease the variability of busulfan plasma concentration by busulfan dose adjustment based on first dose pharmacoin busulfan levels occurring with consecutive doses. 2, 14 For example, a decrease in busulfan plasma levels over the 4 kinetics. Targeted plasma levels were reliably achieved with dose adjustment. Comparison with previous experiday treatment period has been reported by Hassan et al 15 in about 40% of adults and children, suggesting that busulence showed no improvement in VOD occurrence or BMT outcome. However, as more conditioning agents are added fan can induce its own metabolism. However, recently this alteration in busulfan plasma level was attributed to conto the regimen it becomes difficult to obtain relationships between outcome and exposure to any one of the agents. comitant administration of phenytoin used as seizure prophylaxis. Phenytoin and phenobarbital have been shown
Dix et al 24 were also able to achieve the desired busulfan plasma levels with dose adjustment without affecting VOD to decrease the lethal effects of a myeloablative dose of busulfan in mice 16 suggesting that simultaneous adminisfrequency. As dose adjustments were made very late, reduction in toxicity may not have been seen. tration of drugs that alter liver metabolism can affect busulfan kinetics. In our study, patients received anticonvulsant
The incidence of VOD in our study was low -4.5%. There was no correlation with plasma busulfan exposure prophylaxis although most received clonazepam and not phenytoin or phenobarbital. Kinetics of first and last busuland VOD (Figure 2 ). Only one patient had busulfan plasma level above the critical concentration obtained by Grochow fan doses were similar, showing no evidence of accumulation or decrease in plasma levels over time. We conclude et al, 3 1500 m*min (2855 m*min) and he did not develop VOD. We conclude that in younger thalassemia that measurement of first-dose kinetics is sufficient for assessment of busulfan exposure during BMT conditioning patients undergoing HLA-identical BMT monitoring of plasma busulfan level does not have predictive value for in children and young adults with homozygous ␤-thalassemia if there are no changes in subsequent busulfan doses. the development of VOD. A syndrome that occurs rarely and usually only after Variations in plasma pharmacokinetics have been described to be age dependent. Grochow et al 2 reported long-term or high-dose busulfan therapy is known as 'busulfan lung'. Interstitial pneumonitis with lethal outcome that children between 2 months and 5 years demonstrated differences in busulfan disposition when compared with was initially reported in a high proportion of patients receiving conditioning doses of busulfan/CY. However, adults. 2 Hassan et al 17 found children younger than 5 years to have a shorter busulfan elimination half live. In our sersubsequent studies have shown an incidence similar to or less than that observed after CY with total body ies, which included children and young adults, there is no association between age and busulfan pharmacokinetics. It irradiation. 25 In our study, busulfan exposure did not influence occurrence of pneumonitis. suggests that in the context of BMT for thalassemia there is no need for adjustment of busulfan dose based on body Seizures have been reported during treatment with highdose busulfan at any time from the second dose up to 24 surface area in children which has been reported to be associated with increased extrahematological toxicities. 18 h following the final dose. 4 We did not observe seizures during this time period although all patients received antiWe also failed to show an association between busulfan clearance and pre-transplant liver status. In our patient convulsant prophylaxis. The occurrence of seizures later following BMT were not related to the busulfan pharmapopulation with a wide spectrum of liver damage (documented by liver biopsy) secondary to multiple transcokinetic parameters analyzed. Our results suggest that graft rejection following prepfusions and hepatitis there is no evidence of busulfan clearance being affected by liver function. Other studies have aration with conventional doses of busulfan and CY does not correlate with busulfan concentration. Slattery et al 5 shown that pre-existing liver disease with elevated AST and ALT are significant pre-transplant risk factors for demonstrated low steady-state busulfan concentrations (Css Ͻ200 ng/ml) in patients rejecting their graft after partially developing VOD regardless of the conditioning regimen. 19 We observed that the degree of siderosis on liver biopsy HLA-matched sibling or matched unrelated donor BMT.
